Product Description
Mechanisms of Action: ADORA Analogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioCryst
Company Location: DURHAM NC 27703
Company CEO: Jon P. Stonehouse
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Filoviridae Infections|Hemorrhagic Fever, Ebola|Communicable Diseases|Yellow Fever|Marburg Virus Disease|COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| BCX4430-108 | P1 |
Terminated |
COVID-19|Yellow Fever |
2021-01-31 |
62% |
2021-05-28 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| BCX4430-106 | P1 |
Completed |
Marburg Virus Disease |
2019-04-30 |
88% |
2021-02-22 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| BCX4430-101 | P1 |
Completed |
Communicable Diseases|Hemorrhagic Fever, Ebola|Filoviridae Infections |
2016-03-01 |
2019-03-20 |
Treatments |